Ascendiant Capital Markets Cuts Alzamend Neuro (NASDAQ:ALZN) Price Target to $42.00

Alzamend Neuro (NASDAQ:ALZN) had its price objective reduced by Ascendiant Capital Markets from $45.00 to $42.00 in a research report sent to investors on Thursday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Wall Street Zen cut Alzamend Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Alzamend Neuro has an average rating of “Buy” and a consensus target price of $42.00.

Alzamend Neuro Price Performance

NASDAQ:ALZN opened at $2.41 on Thursday. The firm has a fifty day simple moving average of $2.47 and a 200 day simple moving average of $4.25. Alzamend Neuro has a 1-year low of $2.06 and a 1-year high of $17.10.

Insider Buying and Selling at Alzamend Neuro

In related news, Director Milton C. Ault III sold 14,628 shares of the firm’s stock in a transaction dated Thursday, September 25th. The stock was sold at an average price of $2.31, for a total value of $33,790.68. Following the sale, the director directly owned 11,254 shares of the company’s stock, valued at $25,996.74. This trade represents a 56.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 440,435 shares of company stock worth $1,092,722. 30.21% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC acquired a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro as of its most recent SEC filing. 49.61% of the stock is currently owned by institutional investors and hedge funds.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.